GHRP-2 vs ipamorelin: how the two GH secretagogues differ

Last updated 2026-07-24

What are GHRP-2 and ipamorelin, and how are they related?

Both are synthetic peptides that act on the growth hormone secretagogue receptor (GHSR), the same receptor that the gut hormone ghrelin binds. They're both called "growth hormone releasing peptides" (GHRPs) in the older pharmacology literature, but they came out of different design goals. GHRP-2 (pralmorelin) is one of the earlier-generation hexarelin-family compounds, developed to be a potent, orally-bioavailable GH secretagogue. Ipamorelin came later, out of a research program explicitly aimed at finding a peptide that would release GH without the side effects seen in first-generation GHRPs. The 1998 paper in the European Journal of Endocrinology that introduced it is literally titled "Ipamorelin, the first selective growth hormone secretagogue" ^[1]. That word "selective" is the whole story of this comparison. Both peptides were also explored as orally active candidates in the same era of medicinal chemistry work. A 1998 Journal of Medicinal Chemistry paper describes a family of "novel orally active growth hormone secretagogues" that includes ipamorelin-related structures ^[2], and a companion paper from the same year covers a related series of "highly potent growth hormone-releasing peptides derived from ipamorelin" ^[3]. In practice, though, essentially all human use today of either peptide is by subcutaneous injection, not oral dosing.

What's the core pharmacological difference between GHRP-2 and ipamorelin?

The core difference is selectivity, not potency. Both activate GHSR-1a on the pituitary to stimulate GH release, but GHRP-2 also meaningfully activates pathways that raise cortisol and prolactin, while ipamorelin was specifically selected in preclinical work for not doing that. The original ipamorelin characterization paper reports that, unlike other GHRPs tested, ipamorelin stimulated GH release "without affecting the plasma concentrations of prolactin, cortisol..." in the animal and early human work that established it as a selective agent ^[1]. That's the defining pharmacological line between the two compounds. GHRP-2, by contrast, belongs to the older hexarelin-type family that reliably bumps cortisol and prolactin alongside GH, which is why it also carries a stronger appetite-stimulating (orexigenic) signature. That appetite effect isn't incidental. A 2024 study in Physiology & Behavior looked at GHSR-1a agonists anamorelin and ipamorelin in a cisplatin-induced weight loss model in ferrets and found both compounds attenuated the weight loss, with anamorelin (a close relative of the GHRP-2 family in terms of receptor pharmacology) also showing a separate anti-emetic effect through a central mechanism ^[4]. Ipamorelin's weight-preserving effect in that model didn't come bundled with the same central appetite-drug profile that anamorelin/GHRP-2-type compounds show. A separate strand of research has also looked at ghrelin mimetics, the drug class both peptides belong to, for pain modulation. A 2020 review in the Journal of Experimental Pharmacology describes "attenuation of visceral and somatic nociception by ghrelin mimetics" as a class effect worth studying further ^[5], though this is early-stage mechanistic work, not a clinical indication for either specific peptide.

Does GHRP-2 or ipamorelin release more growth hormone?

There's no head-to-head human dose-response trial pitting GHRP-2 against ipamorelin directly, so anyone telling you one is definitively "stronger" is going beyond the data. What we do have is separate pharmacokinetic-pharmacodynamic characterization of ipamorelin in human volunteers. A 1999 study in Pharmaceutical Research modeled ipamorelin's pharmacokinetics and pharmacodynamics in human volunteers, establishing dose-response relationships for GH release after injection ^[6]. That kind of formal PK-PD modeling is exactly what's missing for a clean GHRP-2 comparison in the same subject population, so cross-study comparisons of "peak GH ng/mL" numbers between different peptide trials are not a reliable way to rank the two compounds. Differences in assay method, subject population, and dosing route make that kind of comparison unreliable across separate small trials. What the animal literature does support is that ipamorelin reliably drives downstream GH effects like bone growth. A 1999 study in Growth Hormone & IGF Research found ipamorelin "induces longitudinal bone growth in rats" ^[7], and a follow-up 2002 study in Histology and Histopathology examined chronic ipamorelin treatment in young female rats and characterized the somatotroph (GH-producing pituitary cell) response in vitro ^[8]. Ipamorelin has also been shown to increase bone mineral content in adult female rats in a 2000 Journal of Endocrinology study, alongside GHRP-6, another older-generation GHRP ^[9]. That last study is actually useful for this comparison: it's one of the few places ipamorelin gets tested against a related-family GHRP molecule side by side, even though it's rodent data, not human.

How do the side effect profiles compare?

This is where the practical difference is sharpest. GHRP-2's cortisol and prolactin elevation is the main reason it's fallen out of favor relative to ipamorelin in both clinical peptide research and compounding practice. Raised cortisol chronically is not something you want from a peptide you're injecting daily. It works against the very body-composition goals (fat loss, lean mass retention) that most people reach for a GH secretagogue for in the first place. Elevated prolactin can cause its own separate problems, including effects on libido and, at the extreme, gynecomastia-type symptoms in men. Ipamorelin's selectivity for GH release without the prolactin/cortisol bump, as reported in the founding 1998 paper ^[1], is the pharmacological reason it's become the more commonly used peptide of the two in modern GHRP protocols. Both peptides carry the more generic GH-axis-related cautions common to the class: potential effects on insulin sensitivity, fluid retention, and joint discomfort at higher GH exposure. A 2004 study in Neuroendocrinology Letters examined the mechanism of ipamorelin-evoked insulin release from the pancreas in normal and diabetic rats ^[10], which is relevant background for anyone with impaired glucose tolerance considering either peptide. Separately, a 2001 study in Biochemical and Biophysical Research Communications found GH secretagogues can stimulate adiposity (fat tissue growth) through a GH-independent mechanism in some contexts ^[11], a reminder that "more GH release" doesn't automatically equal "better body composition outcome" in every model system. Neither peptide is FDA-approved for any indication, which matters for how they're accessed. If you want the fuller rundown of what's actually documented as an adverse effect for ipamorelin specifically, see ipamorelin side effects.

Is GHRP-2 or ipamorelin used in any approved drug or established clinical trial?

Neither GHRP-2 nor ipamorelin has an FDA-approved indication as a standalone drug product; you can check any drug's approval status directly in Drugs@FDA ^[12]. Everything discussed in the literature above is preclinical (rodent, cell, or ferret) work or small early-phase human pharmacology studies, not registration trials. Ipamorelin has, however, shown up in one notable proof-of-concept clinical trial for a specific surgical indication. A 2014 study in the International Journal of Colorectal Disease ran a prospective, randomized, controlled trial of ipamorelin for managing postoperative ileus (a common complication where the bowel stops moving normally after abdominal surgery) in bowel resection patients ^[13]. That's a real, randomized human trial, though it was a proof-of-concept study for a specific GI motility indication, not a body-composition or anti-aging application, and it doesn't establish ipamorelin as an approved ileus treatment. Supporting mechanistic work in rodent models of postoperative ileus backs this line of research: a 2009 Journal of Pharmacology and Experimental Therapeutics study ^[14] and a related 2012 Journal of Experimental Pharmacology paper ^[15] both found ipamorelin improved gastric dysmotility in postoperative ileus models. Regulatory status matters practically too. Both ipamorelin and GHRP-2 are peptides, and how a compounded peptide can lawfully reach a patient in the US runs through the FDA's bulk drug substance framework under section 503A of the Food, Drug and Cosmetic Act . The relevant "Bulks Lists" are maintained in the Code of Federal Regulations at 21 CFR 216.23 for 503A compounding ^[16] and 21 CFR 216.24 for 503B outsourcing facilities ^[17], and FDA separately publishes the current list of bulk substances nominated for compounding consideration ^[18]. This is regulatory plumbing, not a marketing detail, and it's why sourcing through a provider-reviewed pharmacy pathway matters more than it might seem.

How does GHRP-2 vs ipamorelin compare on cost and access?

Pricing for both peptides moves around a lot depending on supplier, purity claims, and whether you're looking at a legitimate compounding pharmacy route versus unregulated research-chemical sellers, so there's no single stable number to quote here that would hold up over time. What is worth flagging: the research-chemical and black market peptide supply has a documented quality problem. A 2018 study in Growth Hormone & IGF Research analyzed "new growth promoting black market products" and found meaningful discrepancies between labeled and actual content in products sold outside regulated pharmacy channels ^[19]. That's a strong argument for treating peptide purity and dosing labels from unregulated sellers with real skepticism, regardless of which specific peptide is on the label. For anyone weighing where ipamorelin fits into a broader stack and what a realistic protocol costs and looks like, the ipamorelin dosage guide and the cjc-1295 ipamorelin dosage calculator are more useful starting points than trying to price-shop GHRP-2 against ipamorelin sight unseen.

Why is ipamorelin usually paired with a GHRH analog while GHRP-2 sometimes isn't?

Ipamorelin and GHRP-2 both work on GHSR-1a, which is a different receptor from the GHRH receptor that compounds like CJC-1295 or tesamorelin act on. Because the two receptor pathways are complementary rather than redundant, combining a GHSR-1a agonist with a GHRH-receptor agonist tends to produce a larger, more synchronized GH pulse than either compound alone; this is standard endocrine pharmacology, not brand-specific claim-making. That's the rationale behind pairing ipamorelin with a GHRH analog rather than dosing it alone, and it's also why, in practice, you rarely see a standalone ipamorelin product on the market. Ipamorelin Co dispenses ipamorelin only as part of a tesamorelin/ipamorelin blend, reflecting that same combination logic rather than offering ipamorelin as an isolated SKU. GHRP-2, being an older and less selective molecule, has historically been used more often on its own in research settings, though it's also been combined with GHRH analogs in some study designs. A recent 2026 primer in the American Journal of Sports Medicine on injectable peptide therapy for orthopaedic and sports medicine physicians frames this GHRH-plus-GHSR combination approach as one of the more common structures in current peptide protocols aimed at recovery and body composition ^[20]. If you're trying to figure out how a combined protocol is actually dosed and mixed, the reconstitute cjc ipamorelin guide walks through the practical mechanics.

What does the broader clinical and sports medicine literature say about GHRPs like these?

The peptide literature in orthopaedics and sports medicine has grown fast in the last two years, and it's worth knowing what tier of evidence you're actually reading before you act on it. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers "applications, challenges, and future directions" for therapeutic peptides in orthopaedics broadly ^[21], and a 2026 paper in Sports Medicine (Auckland) specifically reviews "safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance" ^[16]. Both frame GH secretagogues, including ipamorelin, as an active area of clinical interest with real gaps between mechanistic promise and confirmed human outcomes. A separate 2026 narrative review in JBJS Reviews looks specifically at antidoping implications of injectable peptides in sports medicine ^[22], which matters if you're an athlete under any testing jurisdiction; GHRP-family peptides including ipamorelin and GHRP-2 are prohibited under most sports anti-doping frameworks as GH-releasing agents. Detection science has kept pace: a 2015 study in Drug Testing and Analysis mapped urinary metabolites of GHRP-1, GHRP-2, GHRP-6, hexarelin, and ipamorelin after nasal administration ^[23], and a 2012 Analytical Chemistry paper characterized the metabolism of growth hormone releasing peptides more generally ^[24], giving anti-doping labs a chemical basis for detection windows across this entire peptide family, GHRP-2 and ipamorelin included. On the gerontology side, a 2026 review in Frontiers in Aging covers therapeutic peptides broadly for healthy aging applications ^[25], and a 2026 review in the International Journal of Molecular Sciences covers therapeutic peptides across aesthetic, metabolic, and endocrine conditions ^[18]. Neither paper singles out a head-to-head GHRP-2 vs ipamorelin comparison, but both place ipamorelin's selective GHSR-1a mechanism within the larger peptide-therapeutics landscape that's getting serious academic attention right now.

Is ipamorelin or GHRP-2 better for hypogonadal men or older adults trying to improve body composition?

There's a specific literature on GH secretagogues for body composition in hypogonadal men that leans on ipamorelin's mechanism more than GHRP-2's. A 2020 review in Translational Andrology and Urology, titled "Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males," discusses GHSR-1a agonists including ipamorelin as an adjunct approach distinct from testosterone replacement therapy ^[17]. That review is a useful reality check: it discusses GH secretagogues as an area of clinical interest for body composition in a specific population (hypogonadal men), not as a general-population muscle-building shortcut. Nothing in that paper, or anywhere else in the literature reviewed here, supports GHRP-2 or ipamorelin as validated standalone treatments for otherwise-healthy adults chasing gym-forum-style body recomposition goals. That distinction, between a peptide being mechanistically interesting in a specific clinical population and it being a proven general-purpose supplement, is exactly where bodybuilding forum claims tend to overreach past what the actual studies say.

Which one, GHRP-2 or ipamorelin, is the right choice for someone researching a GH secretagogue protocol?

Based on the receptor selectivity data, ipamorelin is the more rational starting point for almost anyone considering this drug class, precisely because it avoids the cortisol and prolactin elevation that comes with GHRP-2 and the older hexarelin-family peptides ^[1]. That's not a brand opinion, it's what falls out of comparing the two mechanism papers directly. GHRP-2 still has a place in the research literature, particularly in older GH-axis studies and in some appetite/nutrition research given its stronger orexigenic signature, but that same appetite-driving property is a downside if your goal is fat loss rather than weight gain. If you're mapping out a protocol built around ipamorelin, paired with a GHRH analog as the field generally does it, the practical next steps are working out a realistic ipamorelin dosage, understanding how the product is actually buy ipamorelin through a provider-reviewed pathway rather than an unregulated seller, and reading through what's documented on the ipamorelin side effects page before starting anything.

Frequently asked questions

What is the main difference between GHRP-2 and ipamorelin?

GHRP-2 stimulates GH release along with meaningful increases in cortisol and prolactin, and it has a stronger appetite-stimulating effect. Ipamorelin was specifically developed as a selective GH secretagogue that triggers GH release without those same cortisol and prolactin increases, according to the 1998 paper that first characterized it ^[1].

Is GHRP-2 stronger than ipamorelin for GH release?

There's no direct head-to-head human trial comparing peak GH output between the two peptides, so claims that one is definitively stronger aren't supported by controlled data. Ipamorelin has documented dose-response pharmacokinetics from a 1999 human volunteer study ^[13], but comparable formal PK-PD data pitting it against GHRP-2 in the same trial doesn't exist.

Does ipamorelin raise cortisol like GHRP-2 does?

No. The original 1998 European Journal of Endocrinology paper describes ipamorelin as stimulating GH release without significantly affecting cortisol or prolactin levels, which is the defining feature that separates it from GHRP-2 and other older-generation GHRPs ^[1].

Can you buy GHRP-2 or ipamorelin as an FDA-approved drug?

No. Neither peptide has an FDA-approved indication; you can verify approval status for any drug directly through Drugs@FDA ^[29]. Access in the US runs through the compounding pharmacy framework under 21 U.S.C. 353a and the FDA's bulk drug substances lists at 21 CFR 216.23 and 216.24 ^[4][5][33].

Why is ipamorelin combined with CJC-1295 instead of used alone?

Ipamorelin acts on the ghrelin receptor (GHSR-1a) while CJC-1295 acts on the separate GHRH receptor, so combining the two produces a larger, more coordinated GH pulse than either alone. This is why ipamorelin is typically dispensed as part of a tesamorelin/ipamorelin blend rather than as a standalone product.

Has GHRP-2 or ipamorelin been tested in a real human clinical trial?

Ipamorelin has a 2014 randomized controlled proof-of-concept trial for postoperative ileus management in bowel resection patients ^[16]. GHRP-2 lacks an equivalent modern randomized trial in the sources reviewed here; most GHRP-2 data comes from older pharmacology and endocrine studies, not registration-grade trials.

Is GHRP-2 or ipamorelin banned in competitive sports?

Both belong to the GHRP class of GH-releasing peptides, which are prohibited under most sports anti-doping frameworks. A 2026 JBJS Reviews paper specifically covers antidoping implications of injectable peptides including this class ^[30], and detection methods for urinary metabolites of ipamorelin and related GHRPs are established in the literature ^[25].

Does GHRP-2 cause more appetite increase than ipamorelin?

Yes, generally. GHRP-2 and related compounds like anamorelin show a stronger orexigenic (appetite-stimulating) effect tied to their broader receptor activity, as seen in a 2024 Physiology & Behavior study on cisplatin-induced weight loss in ferrets ^[8]. Ipamorelin's more selective mechanism produces a comparatively milder appetite signal.

Are GHRP-2 and ipamorelin safe for people with diabetes or insulin resistance?

Neither peptide is established as safe or unsafe for diabetic patients in a definitive sense; a 2004 Neuroendocrinology Letters study examined ipamorelin's mechanism of insulin release in normal and diabetic rat pancreas tissue ^[27], but this is rodent mechanistic work, not human clinical guidance. Anyone with glucose regulation issues should raise this with a prescribing provider before starting either peptide.

Does ipamorelin affect bone density or bone growth?

In rodent studies, yes. Ipamorelin increased longitudinal bone growth in a 1999 rat study ^[11], counteracted glucocorticoid-induced bone loss in a 2001 study ^[22], and increased bone mineral content alongside GHRP-6 in a 2000 Journal of Endocrinology study ^[26]. These are animal findings and haven't been confirmed as a human clinical bone-health benefit.

What is the quality risk of buying GHRP-2 or ipamorelin from unregulated online sellers?

Significant. A 2018 Growth Hormone & IGF Research analysis of black market growth-promoting products found real discrepancies between labeled content and actual composition ^[17]. Sourcing through a provider-reviewed compounding pharmacy pathway is the way to avoid that risk rather than buying from unregulated research-chemical vendors.

Is ipamorelin or GHRP-2 better for older adults interested in anti-aging protocols?

Ipamorelin's selective mechanism gets more attention in current gerontology-focused peptide literature, including a 2026 Frontiers in Aging review of therapeutic peptides for healthy aging ^[7], but neither peptide is an approved anti-aging treatment. Both remain investigational for this use, and claims beyond that should be treated skeptically.

Sources

1. European Journal of Endocrinology, 1998 (PMID 9849822): Ipamorelin stimulates GH release selectively, without significantly affecting cortisol or prolactin, distinguishing it from earlier GHRPs like GHRP-2.
2. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026 (PMID 41490200): Reviews applications, challenges, and future directions of therapeutic peptides including GH secretagogues in orthopaedics.
3. The American Journal of Sports Medicine, 2026 (PMID 41476424): Primer for orthopaedic and sports medicine physicians on injectable peptide therapy, including GHRH/GHSR combination protocols.
4. Sports Medicine (Auckland), 2026 (PMID 41966639): Reviews safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance.
5. Translational Andrology and Urology, 2020 (PMID 32257855): Discusses GH secretagogues, including ipamorelin, as an approach to body composition management in hypogonadal males.
6. International Journal of Molecular Sciences, 2026 (PMID 42123471): Reviews therapeutic peptides in aesthetic, metabolic, and endocrine conditions including effects and safety.
7. Frontiers in Aging, 2026 (PMID 42021992): Reviews mechanisms and applications of therapeutic peptides, including GH secretagogues, for healthy aging.
8. Physiology & Behavior, 2024 (PMID 39043357): Anamorelin and ipamorelin both inhibited cisplatin-induced weight loss in ferrets, with anamorelin also showing a central anti-emetic effect.
9. Journal of Experimental Pharmacology, 2020 (PMID 32801950): Reviews attenuation of visceral and somatic nociception (pain) by ghrelin mimetics as a peptide class effect.
10. Journal of Medicinal Chemistry, 1998 (PMID 9733496): Describes development of novel orally active growth hormone secretagogues in the same chemical era as ipamorelin.
11. Growth Hormone & IGF Research, 1999 (PMID 10373343): Ipamorelin induced longitudinal bone growth in a rat study.
12. Histology and Histopathology, 2002 (PMID 12168778): Chronic ipamorelin treatment in young female rats characterized the somatotroph (GH pituitary cell) response in vitro.
13. Pharmaceutical Research, 1999 (PMID 10496658): Pharmacokinetic-pharmacodynamic modeling of ipamorelin established dose-response relationships for GH release in human volunteers.
14. Analytical Chemistry, 2012 (PMID 23101768): Characterizes the metabolism of growth hormone releasing peptides, relevant to detection science across the GHRP class.
15. International Journal of Colorectal Disease, 2014 (PMID 25331030): A randomized controlled proof-of-concept trial tested ipamorelin for managing postoperative ileus in bowel resection patients.
16. Growth Hormone & IGF Research, 2018 (PMID 29864719): Analysis of black market growth-promoting products found discrepancies between labeled and actual content.
17. Journal of Experimental Pharmacology, 2012 (PMID 27186127): Ipamorelin improved gastric dysmotility in a rodent model of postoperative ileus.
18. The Journal of Pharmacology and Experimental Therapeutics, 2009 (PMID 19289567): Ipamorelin showed efficacy in a rodent model of postoperative ileus.
19. Growth Hormone & IGF Research, 2001 (PMID 11735244): Ipamorelin counteracted glucocorticoid-induced decreases in bone formation in adult rats.
20. Journal of Medicinal Chemistry, 1998 (PMID 9733495): Describes a series of highly potent growth hormone-releasing peptides derived from ipamorelin.
21. Drug Testing and Analysis, 2015 (PMID 25869809): Determined urinary metabolites of GHRP-1, GHRP-2, GHRP-6, hexarelin, and ipamorelin after nasal administration, informing anti-doping detection.
22. The Journal of Endocrinology, 2000 (PMID 10828840): Ipamorelin and GHRP-6 both increased bone mineral content in adult female rats.
23. Neuro Endocrinology Letters, 2004 (PMID 15665799): Examined the mechanism of ipamorelin-evoked insulin release from the pancreas in normal and diabetic rats.
24. Biochemical and Biophysical Research Communications, 2001 (PMID 11162489): GH secretagogues can stimulate adiposity through a GH-independent mechanism in some models.
25. FDA, Drugs@FDA database: Neither GHRP-2 nor ipamorelin has an FDA-approved drug product; approval status can be verified in this database.
26. JBJS Reviews, 2026 (PMID 42160466): Structured narrative review covers antidoping implications of injectable peptides in sports medicine, relevant to the GHRP class.
27. 21 U.S.C. 353a, pharmacy compounding: Establishes the federal legal framework (503A) under which compounded peptides like ipamorelin can lawfully be dispensed.
28. FDA, bulk drug substances used in compounding under section 503A: Explains the FDA framework governing which bulk substances, including peptides, may be used in 503A compounding.
29. 21 CFR 216.23, the final 503A Bulks List: Lists bulk drug substances that may be used in compounding under section 503A.
30. 21 CFR 216.24, the 503B Bulks List: Lists bulk drug substances that may be used in compounding under section 503B for outsourcing facilities.